Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AUGX

AUGX - Augmedix, Inc. Stock Price, Fair Value and News

4.41USD-0.11 (-2.43%)Market Closed
Watchlist

Market Summary

USD4.41-0.11
Market Closed
-2.43%

AUGX Stock Price

View Fullscreen

AUGX RSI Chart

AUGX Valuation

Market Cap

182.4M

Price/Earnings (Trailing)

-9

Price/Sales (Trailing)

4.46

EV/EBITDA

-9.15

Price/Free Cashflow

-8.54

AUGX Price/Sales (Trailing)

AUGX Profitability

Operating Margin

47.23%

EBT Margin

-48.96%

Return on Equity

-2.8K%

Return on Assets

-49.66%

Free Cashflow Yield

-11.71%

AUGX Fundamentals

AUGX Revenue

Revenue (TTM)

40.9M

Rev. Growth (Yr)

49.63%

Rev. Growth (Qtr)

9.16%

AUGX Earnings

Earnings (TTM)

-20.3M

Earnings Growth (Yr)

19.73%

Earnings Growth (Qtr)

12.44%

Breaking Down AUGX Revenue

Last 7 days

7.8%

Last 30 days

-6.4%

Last 90 days

4.2%

Trailing 12 Months

187.1%

How does AUGX drawdown profile look like?

AUGX Financial Health

Current Ratio

1.34

AUGX Investor Care

Shares Dilution (1Y)

10.50%

Diluted EPS (TTM)

-0.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202333.6M37.0M40.9M0
202224.4M26.5M28.8M30.9M
202117.3M18.8M20.1M22.2M
202014.7M15.3M15.9M16.5M
201900014.1M

Tracking the Latest Insider Buys and Sells of Augmedix, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 15, 2023
faulkner robert c.
acquired
-
-
1,767
-
Dec 15, 2023
redmile group, llc
acquired
-
-
1,767
-
Nov 22, 2023
ginocchio paul
bought
48,500
4.85
10,000
chief financial officer
Nov 20, 2023
redmile group, llc
bought
3,000,000
4.00
750,000
-
Aug 31, 2023
redmile group, llc
acquired
9,999
4.78
2,092
-
Aug 31, 2023
faulkner robert c.
acquired
9,999
4.78
2,092
-
Jul 13, 2023
faulkner robert c.
acquired
-
-
21,598
-
Jul 13, 2023
redmile group, llc
acquired
-
-
21,598
-
Jun 16, 2023
marks joseph
acquired
-
-
52,632
-

1–10 of 50

Which funds bought or sold AUGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
Spouting Rock Asset Management, LLC
reduced
-9.00
11,105
340,540
0.12%
Feb 15, 2024
JANE STREET GROUP, LLC
added
901
667,115
731,402
-%
Feb 15, 2024
TOWNSQUARE CAPITAL LLC
reduced
-57.74
-648,008
598,159
0.01%
Feb 15, 2024
BARCLAYS PLC
reduced
-15.51
-5,000
110,000
-%
Feb 14, 2024
Point72 Asia (Singapore) Pte. Ltd.
new
-
8,354
8,354
-%
Feb 14, 2024
EAM Investors, LLC
reduced
-65.75
-1,164,170
741,218
0.13%
Feb 14, 2024
Quantbot Technologies LP
new
-
65,052
65,052
-%
Feb 14, 2024
AWM Investment Company, Inc.
new
-
1,442,580
1,442,580
0.19%
Feb 14, 2024
BOOTHBAY FUND MANAGEMENT, LLC
added
2.19
116,766
842,798
0.02%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
new
-
1,379,430
1,379,430
-%

1–10 of 45

Are Funds Buying or Selling AUGX?

Are funds buying AUGX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AUGX
No. of Funds

Unveiling Augmedix, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 26, 2024
dcm vi, l.p.
0.6%
269,490
SC 13D/A
Feb 09, 2024
samjo management, llc
6.1%
2,957,000
SC 13G
Jan 30, 2024
dcm vi, l.p.
6.8%
3,328,014
SC 13D/A
Jan 11, 2024
dcm vi, l.p.
7.9%
3,835,278
SC 13D/A
Dec 29, 2023
dcm vi, l.p.
9.1%
4,438,408
SC 13D/A
Nov 22, 2023
redmile group, llc
40.7%
22,092,211
SC 13D/A
Nov 03, 2023
dcm vi, l.p.
10.9%
0
SC 13D/A
Jun 15, 2023
redmile group, llc
44.7%
20,246,320
SC 13D/A
May 04, 2023
redmile group, llc
44.7%
20,246,320
SC 13D/A
Apr 21, 2023
redmile group, llc
44.7%
20,246,320
SC 13D/A

Recent SEC filings of Augmedix, Inc.

View All Filings
Date Filed Form Type Document
Feb 27, 2024
4
Insider Trading
Feb 27, 2024
4
Insider Trading
Feb 27, 2024
4
Insider Trading
Feb 27, 2024
4
Insider Trading
Feb 27, 2024
4
Insider Trading
Feb 27, 2024
4
Insider Trading
Feb 26, 2024
SC 13D/A
13D - Major Acquisition
Feb 09, 2024
SC 13G
Major Ownership Report
Jan 30, 2024
SC 13D/A
13D - Major Acquisition
Jan 11, 2024
SC 13D/A
13D - Major Acquisition

Peers (Alternatives to Augmedix, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
460.9B
360.0B
0.01% 5.90%
21.25
1.28
14.24% 11.62%
94.6B
357.8B
0.71% -14.01%
11.33
0.26
10.95% 93.52%
82.6B
65.0B
9.34% 20.24%
15.76
1.27
7.86% -7.11%
42.9B
154.0B
-0.09% 8.25%
15.87
0.28
6.54% 124.79%
11.1B
12.1B
12.03% 47.11%
16.1
0.92
4.57% 23.40%
11.1B
14.3B
2.25% 10.28%
15.51
0.78
6.59% 6.24%
MID-CAP
9.5B
2.2B
0.13% 16.69%
38.7
4.25
4.50% -6.69%
7.7B
2.9B
-3.46% 1.96%
-421.06
2.69
13.16% -106.47%
2.1B
3.8B
-19.95% -33.62%
9.84
0.55
-27.73% -52.50%
SMALL-CAP
2.5B
1.3B
4.99% 11.37%
57.12
1.92
27.06% -27.04%
1.4B
1.1B
8.40% -11.51%
23.13
1.37
11.31% 35.83%
994.0M
3.0B
7.30% 124.36%
-5.26
0.33
6.74% 20.73%
37.4M
-
-0.60% -54.62%
-2.58
-
- -27.68%
17.1M
20.7M
- -15.62%
84.41
0.83
6.53% -85.60%

Augmedix, Inc. News

Latest updates
AmericanBankingNEWS20 hours ago
MarketBeat17 Feb 202408:54 pm
Yahoo Finance04 Feb 202408:00 am
InvestorPlace3 months ago

Augmedix, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue9.2%11,767,00010,780,0009,628,0008,751,0007,864,0007,333,0006,985,0006,577,0005,625,0005,173,0004,790,0004,543,0204,245,0003,725,0003,969,961-
Cost Of Revenue3.9%5,937,0005,715,0005,242,0004,702,0004,274,0004,131,0003,872,0003,640,0003,092,0002,761,0002,665,0002,535,9132,368,0002,195,0002,590,174-
Gross Profit15.1%5,830,0005,065,0004,386,0004,049,0003,590,0003,202,0003,113,0002,937,0002,533,0002,412,0002,125,0002,007,1071,877,0001,530,0001,379,787-
Operating Expenses2.3%10,233,0009,999,0009,480,0009,489,0009,048,0009,141,0008,647,0007,545,0007,083,0006,447,0006,529,0005,577,0445,232,0004,080,0005,597,912-
  S&GA Expenses3.0%2,729,0002,649,0002,563,0002,339,0002,304,0002,320,0002,320,0001,830,0002,035,0001,728,0001,574,0001,452,986887,000819,0001,239,0283,559,929
  R&D Expenses13.4%2,936,0002,590,0002,710,0002,612,0002,608,0002,649,0002,280,0001,943,0001,810,0001,499,0001,426,0001,036,9551,009,000985,0001,491,091-
EBITDA Margin16.7%-0.43-0.52-0.64-0.72-0.54-0.57-0.62-0.68--------
Interest Expenses-13.7%333,000386,000281,000427,000-365,000450,000323,000460,000437,000393,000633,2081,4581,342320,7851,365,732
Income Taxes64.7%84,00051,00033,00071,00019,0002,00019,000---------
Earnings Before Taxes13.2%-4,323,000-4,982,000-5,206,000-5,528,000-5,471,000-7,333,000-6,006,000---------
EBT Margin14.4%-0.49-0.57-0.70-0.79-0.61-0.66-0.71-0.79--------
Net Income12.4%-4,407,000-5,033,000-5,239,000-5,599,000-5,490,000-7,335,000-6,025,000-5,186,000-2,737,000-4,715,000-4,918,000-3,791,000-4,116,000-2,959,000-4,738,000-18,472,788
Net Income Margin14.1%-0.50-0.58-0.70-0.79-0.84-0.80-0.77-0.79-0.80-0.94-0.91-0.95-1.91---
Free Cashflow62.4%-2,730,000-7,256,000-6,394,000-4,978,000-3,732,000-4,859,000-4,612,000-5,470,000-5,562,000-2,714,000-5,457,000-4,320,000-1,859,000---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-6.9%41.0044.0033.0034.0037.0041.0046.0052.0019.0023.0025.0028.0025.0022.0019.0016.00---
  Current Assets-8.3%33.0036.0028.0030.0033.0036.0043.0051.0018.0022.0024.0027.000.000.0010*14.00154*0.000.00
    Cash Equivalents-12.0%22.0025.0021.0021.0026.0030.0037.0042.0011.0017.0019.0023.003.005.006.0012.00154*0.000.00
  Net PPE15.0%3.003.002.002.001.001.001.001.001.001.001.001.00---1.00---
Liabilities0.6%40.0040.0036.0032.0031.0029.0028.0028.0026.0028.0026.0025.0025.0026.0026.0027.0018.009.000.00
  Current Liabilities16.2%25.0021.0017.0019.0016.0013.0014.0014.0011.0011.0010.0016.000.000.000.0013.000.000.000.00
Shareholder's Equity-81.6%1.004.001281.006.0012.0018.0024.0089.0089.0088.003.004.004.003.003.00---
  Retained Earnings-3.3%-140-136-131-125-120-115-107-101-96.28-93.42-88.78-83.88-0.11-0.09-0.08-68.27-0.06-0.05-0.04
  Additional Paid-In Capital0.9%14214112812812712612612589.0089.0088.0087.00---3.00---
Shares Outstanding1.2%41.0041.0038.0037.0037.0037.0037.0037.0027.0027.0027.0027.00-------
Float------33.00---38.00---------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations61.5%-2,293-5,954-6,221-4,386-3,531-4,697-4,159-5,282-5,457-2,553-5,300-4,100-1,747-2,933-5,618-14,622-12.29-3.72-7.35-
  Share Based Compensation12.7%63756553372047749142439337123938417799.0029597.00-----
Cashflow From Investing66.4%-437-1,302-173-592-201-162-453-188-105-161-157-220-112-58.48-256-----
Cashflow From Financing-99.8%20.0011,8845,0857.004.00-1,26113.0035,946-3.0062.001,82223,864-1252,18049817,1445.008.0011.00-

AUGX Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenues$ 11,767$ 7,864$ 32,175$ 22,182
Cost of revenues5,9374,27416,89412,277
Gross profit5,8303,59015,2819,905
Operating expenses:    
General and administrative4,5684,13613,53512,355
Sales and marketing2,7292,3047,9416,944
Research and development2,9362,6088,2367,537
Total operating expenses10,2339,04829,71226,836
Loss from operations(4,403)(5,458)(14,431)(16,931)
Other income (expenses):    
Interest expense(642)(316)(1,608)(1,302)
Interest income2885972668
Loss on debt extinguishment(1,097)
Change in fair value of warrant liability(36)(105)
Other income470244907452
Total other income (expenses), net80(13)(80)(1,879)
Net loss before income taxes(4,323)(5,471)(14,511)(18,810)
Income tax expense841916840
Net loss(4,407)(5,490)(14,679)(18,850)
Other comprehensive income (loss):    
Foreign exchange translation adjustment(106)(117)(437)(257)
Total comprehensive loss$ (4,513)$ (5,607)$ (15,116)$ (19,107)
Net loss per share of common stock, basic (in Dollars per share)$ (0.1)$ (0.15)$ (0.35)$ (0.5)
Weighted average shares of common stock outstanding, basic (in Shares)45,520,89337,426,75142,236,06337,412,238

AUGX Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 21,593$ 21,251
Restricted cash125125
Accounts receivable, net of allowance for doubtful accounts of $134 and $102 at September 30, 2023 and December 31, 2022, respectively9,4466,354
Prepaid expenses and other current assets1,9061,820
Total current assets33,07029,550
Property and equipment, net3,0001,573
Operating lease right of use asset3,2901,567
Restricted cash, non-current568612
Deposits and other assets905339
Total assets40,83333,641
Current liabilities:  
Loan payable, current portion7,5003,750
Accounts payable1,8161,563
Accrued expenses and other current liabilities5,4725,321
Deferred revenue7,9937,254
Operating lease liability, current portion1,434872
Customer deposits486554
Total current liabilities24,70119,314
Loan payable, net of current portion12,60811,384
Operating lease liability, net of current portion2,079968
Other liabilities711509
Total liabilities40,09932,175
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Common stock, $0.0001 par value; 500,000,000 shares authorized; 41,275,216 and 37,442,663 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively44
Additional paid-in capital142,077127,693
Accumulated deficit(140,470)(125,791)
Accumulated other comprehensive loss(877)(440)
Total stockholders’ equity7341,466
Total liabilities and stockholders’ equity$ 40,833$ 33,641
AUGX
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Notes that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, a self-service mobile software application. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
 CEO
 WEBSITEwww.augmedix.com
 EMPLOYEES1040

Augmedix, Inc. Frequently Asked Questions


What is the ticker symbol for Augmedix, Inc.? What does AUGX stand for in stocks?

AUGX is the stock ticker symbol of Augmedix, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Augmedix, Inc. (AUGX)?

As of Tue Feb 27 2024, market cap of Augmedix, Inc. is 186.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AUGX stock?

You can check AUGX's fair value in chart for subscribers.

What is the fair value of AUGX stock?

You can check AUGX's fair value in chart for subscribers. The fair value of Augmedix, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Augmedix, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AUGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Augmedix, Inc. a good stock to buy?

The fair value guage provides a quick view whether AUGX is over valued or under valued. Whether Augmedix, Inc. is cheap or expensive depends on the assumptions which impact Augmedix, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AUGX.

What is Augmedix, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 27 2024, AUGX's PE ratio (Price to Earnings) is -9.22 and Price to Sales (PS) ratio is 4.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AUGX PE ratio will change depending on the future growth rate expectations of investors.